United States:
FDA Determines LUPRON DEPOT Not Withdrawn For Safety Or Effectiveness Reasons
27 October 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
In the October 8, 2014, Federal Register, FDA published its
determination that LUPRON DEPOT (leuprolide acetate for depot
suspension), an injectable vial containing 3.75 milligrams of the
drug, was not withdrawn from sale for reasons of safety or
effectiveness.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...